Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAHR-102
- Development stage
- Discontinued
- Lead developer
- KAHR Medical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
KAHR-102 is a dual signaling fusion protein that combines cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) with Fas-ligand (FasL). It is designed as an immunotherapy for cancer, particularly lymphoma. The drug acts by antagonizing CD80 and potentially other targets such as CD86 and Fas receptor, thereby modulating immune responses to promote anti-tumor activity. Developed by KAHR Medical, the drug has been evaluated in early-phase clinical trials for its safety, tolerability, and anti-cancer activity in patients with lymphoma expressing both B7 (CD80/CD86) and FasR[1][2][3][5].
- Other names
- CTLA-4/FasL fusion protein
02
Targets
FASLG (Fas ligand)TNFR (TNF receptor family)CD80 (T-lymphocyte activation antigen CD80)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD86 (T-lymphocyte activation antigen CD86)
Beyond the preview
Go deeper on KAHR-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAHR-102.